Cargando…
Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance. Since many patients encountering resistance turn to alternative/complementary treatment...
Autores principales: | Juengel, Eva, Maxeiner, Sebastian, Rutz, Jochen, Justin, Saira, Roos, Frederik, Khoder, Wael, Tsaur, Igor, Nelson, Karen, Bechstein, Wolf O., Haferkamp, Axel, Blaheta, Roman A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356730/ https://www.ncbi.nlm.nih.gov/pubmed/27863441 http://dx.doi.org/10.18632/oncotarget.13421 |
Ejemplares similares
-
Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro
por: Justin, Saira, et al.
Publicado: (2020) -
Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020) -
Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022) -
HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017) -
Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)